Perry A Karsen - Net Worth and Insider Trading
Perry A Karsen Net Worth
The estimated net worth of Perry A Karsen is at least $6 Million dollars as of 2024-09-20. Perry A Karsen is the see remarks of Celgene Corp and owns about 54,869 shares of Celgene Corp (CELG) stock worth over $6 Million. Perry A Karsen is the Director of Intellia Therapeutics Inc and owns about 5,000 shares of Intellia Therapeutics Inc (NTLA) stock worth over $111,500. Perry A Karsen is also the Director of Jounce Therapeutics Inc and owns about 5,000 shares of Jounce Therapeutics Inc (JNCE) stock worth over $9,400. Besides these, Perry A Karsen also holds OncoMed Pharmaceuticals Inc (OMED) . Details can be seen in Perry A Karsen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Perry A Karsen has not made any transactions after 2020-12-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Perry A Karsen
Perry A Karsen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Perry A Karsen owns 9 companies in total, including Jounce Therapeutics Inc (JNCE) , Intellia Therapeutics Inc (NTLA) , and Voyager Therapeutics Inc (VYGR) among others .
Click here to see the complete history of Perry A Karsen’s form 4 insider trades.
Insider Ownership Summary of Perry A Karsen
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| JNCE | Jounce Therapeutics Inc | 2017-02-01 | director |
| NTLA | Intellia Therapeutics Inc | 2020-12-17 | director |
| VYGR | Voyager Therapeutics Inc | 2015-11-10 | director |
 | | 2019-04-23 | director |
| | 2014-11-10 | director |
| | 2013-07-23 | director |
| | 2013-11-27 | director |
| | 2021-06-24 | director |
| | 2020-11-18 | director |
Perry A Karsen Latest Holdings Summary
Perry A Karsen currently owns a total of 4 stocks. Among these stocks, Perry A Karsen owns 54,869 shares of Celgene Corp (CELG) as of November 12, 2014, with a value of $6 Million and a weighting of 97.86%. Perry A Karsen owns 5,000 shares of Intellia Therapeutics Inc (NTLA) as of December 17, 2020, with a value of $111,500 and a weighting of 1.84%. Perry A Karsen also owns 5,000 shares of Jounce Therapeutics Inc (JNCE) as of February 1, 2017, with a value of $9,400 and a weighting of 0.15%. The other 1 stocks OncoMed Pharmaceuticals Inc (OMED) have a combined weighting of 0.15% among all his current holdings.
Latest Holdings of Perry A Karsen
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CELG | Celgene Corp | 2014-11-12 | 54,869 | 108.24 | 5,939,021 |
| NTLA | Intellia Therapeutics Inc | 2020-12-17 | 5,000 | 22.30 | 111,500 |
| JNCE | Jounce Therapeutics Inc | 2017-02-01 | 5,000 | 1.88 | 9,400 |
| OMED | OncoMed Pharmaceuticals Inc | 2017-06-05 | 10,000 | 0.89 | 8,900 |
Holding Weightings of Perry A Karsen
Perry A Karsen Form 4 Trading Tracker
According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 39,420 shares on November 12, 2014, which brought Perry A Karsen around $4 Million.
According to the SEC Form 4 filings, Perry A Karsen has made a total of 1 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 88,764 shares on December 17, 2020, which brought Perry A Karsen around $5 Million.
According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years. The most-recent trade in Jounce Therapeutics Inc is the acquisition of 5,000 shares on February 1, 2017, which cost Perry A Karsen around $80,000.
More details on Perry A Karsen's insider transactions can be found in the Insider Trading History of Perry A Karsen table.Insider Trading History of Perry A Karsen
- 1
Perry A Karsen Trading Performance
GuruFocus tracks the stock performance after each of Perry A Karsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Perry A Karsen is 50.42%. GuruFocus also compares Perry A Karsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Perry A Karsen within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Perry A Karsen's insider trading performs compared to the benchmark.
Performance of Perry A Karsen
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 13.63 | | | | | |
| Relative Return to S&P 500(%) | 11.15 | | | | | |
Perry A Karsen Ownership Network
Perry A Karsen Owned Company Details
What does Jounce Therapeutics Inc do?
Who are the key executives at Jounce Therapeutics Inc?
Perry A Karsen is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .
Jounce Therapeutics Inc (JNCE) Insider Trades Summary
Over the past 18 months, Perry A Karsen made no insider transaction in Jounce Therapeutics Inc (JNCE). Other recent insider transactions involving Jounce Therapeutics Inc (JNCE) include a net sale of 39,228 shares made by Richard /ca/ Murray ,
In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 39,228 shares of Jounce Therapeutics Inc (JNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 39,228 shares.
Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Jounce Therapeutics Inc Insider Transactions
Perry A Karsen Mailing Address
Above is the net worth, insider trading, and ownership report for Perry A Karsen. You might contact Perry A Karsen via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
